摘要
目的研究免疫性血小板减少症(ITP)患者外周血单核细胞(PBMC)中micro RNA-146a(mi R-146a)的表达水平及参芪益气生血合剂体外干预对其表达的影响。方法以荧光定量PCR法,对比ITP组与正常对照组PBMC中mi R-146a表达水平的差异,对比ITP药物干预组(参芪益气生血合剂)患者与ITP空白对照组患者PBMC中mi R-146a表达水平的差异。结果与正常对照组相比,ITP组患者PBMC中mi R-146a表达水平显著降低,差异具有统计学意义(P<0.05);ITP药物干预组患者PBMC中mi R-146a表达水平较ITP空白对照组高,且差异具有统计学意义(P<0.05)。结论 mi R-146a表达异常可能与ITP的发生发展相关,参芪益气生血合剂可能通过参与调节ITP患者的mi R-146a表达达到改善ITP效果。
Objective To investigate the expression of microRNA-146a （miR-146a） in peripheral blood mononuclear cell （PBMC） of immune thrombocytopenic purpura （ITP） patients, and to explore the intervention effect of Shenqi Yiqi Shengxue decoction. Methods The expression of miR-146a in PBMC was detected by fluorescence quantitative PCR in normal human （nomal control group）, ITP patients （ITP control group） and ITP patients with Shenqi Yiqi Shengxue decoction intervention （drug intervention group） were explored. Results The expression of miR-146a in ITP patients group was significantly lower than that in normal control group, and the difference was significant （P〈0.05）. The expression of miR-146a in drug intervention group was higher than that in ITP control group, and the difference was significant （P〈0.05）. Conclusion The abnormal expression of miR-146a may play an important role in the occurrence and development of ITP, and Shenqi Yiqi Shengxue decoction may be involved in regulating miR-146a level and be beneficial to treat ITP.
出处
《世界临床药物》
CAS
2016年第7期457-460,共4页
World Clinical Drug
基金
上海卫生局青年科研项目(编号:20124Y017)
